Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5. EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6. INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DERMATOLOGIST
6.8 OTHER KOL SNAPSHOTS
7. REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8. MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9. PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.4.1 PONEZUMAB
9.4.2 OTHERS
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10. MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 IMMUNOSUPPRESSIVE DRUGS
11.2.1 MOFETIL
11.2.1.1. MARKET VALUE (USD MN)
11.2.1.2. MARKET VOLUME (SU)
11.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.2 MYCOPHENOLATE
11.2.2.1. MARKET VALUE (USD MN)
11.2.2.2. MARKET VOLUME (SU)
11.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.3 METHOTREXATE
11.2.3.1. MARKET VALUE (USD MN)
11.2.3.2. MARKET VOLUME (SU)
11.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.4 OTHERS
11.3 TAXIFOLIN
11.3.1 MARKET VALUE (USD MN)
11.3.2 MARKET VOLUME (SU)
11.3.3 AVERAGE SELLING PRICE (USD)
11.4 GLUCOCORTICOSTEROIDS
11.4.1 PREDNISONE
11.4.1.1. MARKET VALUE (USD MN)
11.4.1.2. MARKET VOLUME (SU)
11.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.2 DEXAMETHASONE
11.4.2.1. MARKET VALUE (USD MN)
11.4.2.2. MARKET VOLUME (SU)
11.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.3 OTHERS
11.5 ADUCANUMAB
11.5.1 MARKET VALUE (USD MN)
11.5.2 MARKET VOLUME (SU)
11.5.3 AVERAGE SELLING PRICE (USD)
11.6 OTHERS
12. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 PEDIATRIC
12.3 ADULT
12.4 GERIATRIC
13. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 NEUROLOGY CLINICS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 ONLINE PHARMACY
14.4 RETAIL PHARMACY
14.5 OTHERS
15. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY GEOGRAPHY
15.1 GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.1.1. U.S. CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY TREATMENT
15.2.1.2. U.S. CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY PATIENT TYPE
15.2.1.3. U.S. CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY SOURCE
15.2.1.4. U.S. CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, BY END USER
15.2.2 CANADA
15.2.3 MEXICO
15.2.4 DOMINICAN REPUBLIC
15.2.5 JAMAICA
15.2.6 PANAMA
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 HUNGARY
15.3.5 LITHUANIA
15.3.6 AUSTRIA
15.3.7 IRELAND
15.3.8 NORWAY
15.3.9 POLAND
15.3.10 ITALY
15.3.11 SPAIN
15.3.12 RUSSIA
15.3.13 TURKEY
15.3.14 NETHERLANDS
15.3.15 SWITZERLAND
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 TAIWAN
15.4.4 SOUTH KOREA
15.4.5 INDIA
15.4.6 AUSTRALIA
15.4.7 SINGAPORE
15.4.8 THAILAND
15.4.9 MALAYSIA
15.4.10 INDONESIA
15.4.11 PHILIPPINES
15.4.12 VIETNAM
15.4.13 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ECUADOR
15.5.3 CHILE
15.5.4 COLOMBIA
15.5.5 VENEZUELA
15.5.6 ARGENTINA
15.5.7 PERU
15.5.8 CURAÇAO
15.5.9 PARAGUAY
15.5.10 URUGUAY
15.5.11 TRINIDAD AND TOBAGO
15.5.12 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 UAE
15.6.4 EGYPT
15.6.5 KUWAIT
15.6.6 ISRAEL
15.6.7 BOLIVIA
15.6.8 REST OF MIDDLE EAST AND AFRICA
15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, SWOT AND DBMR ANALYSIS
17. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18. GLOBAL CEREBRAL AMYLOID ANGIOPATHY TREATMENT MARKET, COMPANY PROFILE
18.1 PFIZER, INC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 JOHNSON & JOHNSON
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 ALLERGEN
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 SANOFI
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 BRISTOL MYERS SQUIBB
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 BAYER AG
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 ASTELLAS PHARMA INC
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 REGENERON PHARMACEUTICALS, INC
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.10 F-HOFFMANN LA ROCHE
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 GLAXOSMITHKLINE PLC
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 MERCK SHARP & DOHME CORP
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 MYLAN NV
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 TEVA PHARMACEUTICALS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 ASTRAZENCA
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 AKORN
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 CIPLA PHARMACEUTICALS
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 LUPIN PHARMA
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.20 SUN PHARMACEUTICALS
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 DR REDDY LABORATORIES
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ZYDUS HEALTHCARE
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 GILEAD SCIENCES
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 ELI LILLY
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 EISAI CO
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19. RELATED REPORTS
20. CONCLUSION
21. QUESTIONNAIRE
22. ABOUT DATA BRIDGE MARKET RESEARCH
